Detailed Coverage

Medplus Health Services Reports Strong Revenue Growth Amidst Margin Pressure in Q1 FY27

Revenue for Q1 FY27 stood at ₹1,879.6 crore (₹18,796 million).
Profit after tax (PAT) was ₹33.2 crore (₹331.7 million).

What just happened

Medplus Health Services announced its financial results for the first quarter of FY27, reporting a consolidated revenue of ₹1,879.6 crore, marking a 21.8% year-on-year increase. However, the company experienced margin compression, with its gross margin decreasing to 24.5% and operating EBITDA margin contracting to 3.5%. Profit after tax (PAT) for the quarter was ₹33.2 crore.

Why this matters

The revenue growth indicates Medplus's continued expansion and market penetration. However, the decline in margins, attributed by management to a shift in sales mix away from private label products and lower franchisee business margins, presents a challenge. Investors will be keen to see if the company can improve profitability alongside its top-line growth.

The backstory

Medplus Health Services is a major pharmacy retail chain in India. The company has been focusing on expanding its store network and also developing its diagnostics business. Recent quarters have seen efforts to balance growth with profitability.

What changes now

The company's focus will likely be on managing its product mix to improve margins and enhancing the performance of its franchisee business. The diagnostics segment's strong EBIT growth offers a positive avenue for future profitability.

Risks to watch

Key risks include the continued pressure on margins, the potential for further store closures, and the company's ability to meet its internal Annual Operating Plan (AOP) targets, as actual Operating EBITDA was 81.6% of the AOP. The closure of 52 stores during the quarter is also a point to monitor.

Peer comparison

While specific peer data for the same quarter isn't provided in the filing, the pharmacy retail sector generally faces competition from both organized and unorganized players, with margins often under pressure due to price competition and inventory management.

Context metrics (time-bound)

• Total stores as of June 30, 2026: 5,476
• Net store additions in Q1 FY27: 146
• Stores closed in Q1 FY27: 52
• Diagnostics segment EBIT growth: 372.5% year-on-year
• Actual revenue vs. AOP: 99.0%
• Actual Operating EBITDA vs. AOP: 81.6%

What to track next

Investors should monitor the company's ability to improve its gross and operating margins in the coming quarters, the performance of the diagnostics segment, and the efficiency of its store expansion strategy, particularly in relation to store closures and meeting internal AOP targets.

Reader Takeaway: Strong revenue growth and diagnostics performance are positive, but margin compression and AOP variance need attention.